Aurobindo Pharma gets USFDA nod to generic equivalent of Ofirmev Injection
Acetaminophen Injection is indicated for the treatment of mild to moderate pain in adult and pediatric patients 2 years and older.
Hyderabad: Drugmaker, Aurobindo Pharma Limited, has recently announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Acetaminophen Injection, 1,000 mg/ 100 mL single-dose vial (SDV). Aurobindo's Acetaminophen Injection is a generic equivalent of Mallinckrodt's Ofirmev Injection. The product will be launched in...
Hyderabad: Drugmaker, Aurobindo Pharma Limited, has recently announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Acetaminophen Injection, 1,000 mg/ 100 mL single-dose vial (SDV).
Aurobindo's Acetaminophen Injection is a generic equivalent of Mallinckrodt's Ofirmev Injection. The product will be launched in December 2020.
Acetaminophen Injection is indicated for the treatment of mild to moderate pain in adult and pediatric patients 2 years and older. The injection is also set to treat moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older, and reduction of fever in adult and pediatric patients.
The approved product has an estimated market size of US$ 339 million for the twelve months ending August 2020 according to IQVIA.
This is the 75th ANDA to be approved out of the Company's Unit IV formulation facility in Hyderabad, India used for manufacturing injectable & ophthalmic products.
Aurobindo now has a total of 449 ANDA approvals (421 Final approvals and 28 tentative approvals) from USFDA.
Read also: Aurobindo Pharma, BIRAC join hands for COVID vaccine development
Aurobindo Pharma Limited, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd